Merck 2Q
2Q Revenues: $11.3 billion (+92%)
2Q Earnings: $780.2 million (-51%)
YTD Revenues: $22.8 billion (earnings were $11.3 billion YTD09)
YTD Earnings: $1.1 billion (-64%)
Comments: Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Zetia sales were $564 million (+1%) and Vytorin sales were $490 million (-8%). Isentress sales jumped 55% to $267 million. Cozaar/Hyzaar sales were down 46% to $485 million due to generic competition. Results in the quarter and YTD include $1.7 billion and $4.0 billion, respectively, of merger-related expenses.
Magazine
